Skip to main content
main-content

01.12.2017 | Letter to the Editor | Ausgabe 1/2017 Open Access

Journal of Hematology & Oncology 1/2017

MiR-194 functions as a tumor suppressor in laryngeal squamous cell carcinoma by targeting Wee1

Zeitschrift:
Journal of Hematology & Oncology > Ausgabe 1/2017
Autoren:
Pei Li, Yang Yang, Hui Liu, An-Kui Yang, Jin-Ming Di, Guang-Mou Tan, Hai-Feng Wang, Jian-Ge Qiu, Wen-Ji Zhang, Qi-Wei Jiang, Di-Wei Zheng, Yao Chen, Meng-Ning Wei, Jia-Rong Huang, Kun Wang, Zhi Shi, Jin Ye
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s13045-017-0402-6) contains supplementary material, which is available to authorized users.
Abbreviations
LSCC
Laryngeal squamous cell carcinoma
UTRs
3’-untranslated regions

Letter to the editor

Laryngeal cancer is the fourteenth most prevalent type of malignancy worldwide in the male compared to its relative rare in the female. Laryngeal squamous cell carcinoma (LSCC) accounts for approximately 90% of all malignant tumors of the larynx [ 1]. Deregulated microRNAs (miRs) are frequently demonstrated as biomarker or therapeutic target in LSCC tissues and cells, which may function as tumor suppressor or oncogene to regulate the malignancy of cancer [ 2]. As one of frequently deregulated miRs in cancer, the expression and role of miR-194 in LSCC are still unknown [ 3, 4].
In the current study, we found that the expression level of miR-194 is significantly lower not only in two LSCC cell lines Hep-2 and KB-3-1 compared with normal human bronchial epithelial cell line 16HBE but also in clinical LSCC tissues compared with adjacent normal tissues and correlated with T stage, lymph node metastasis, and clinical stage, but not with age, tumor grades, and tumor primary locations (Fig.  1b–g, Additional file 1: Figure S1a and Table S1). The miR-194 levels could be a significant parameter to distinguish LSCC and adjacent normal tissues with an area under the ROC curve (AUC) of 0.676 (sensitivity = 63.64%, specificity = 72.72%; P = 0.004) (Fig.  1h). Kaplan–Meier analysis indicated that high miR-194 expression predicts a favorable outcome for LSCC patients (Fig.  1i). Functional assays showed that enforced expression of miR-194 inhibits the growth, migration, invasion, and drug resistance of Hep-2 and KB-3-1 cells in vitro (Additional file 1: Figure S2a–g). The data in the subcutaneous tumor model in nude mice revealed that overexpression of miR-194 significantly inhibited the growth of Hep-2 and KB-3-1 xenografts by the numbers of Ki67 + proliferating cells and CD31 + microvessels (Additional file 1: Figure S3a–d). We used three computational algorithms, including miRanda, PITA, and TargetScan in combination to identify the novel potential targets of miR-194. All three algorithms predicted Wee1 as a target gene of miR-194, which is a protein kinase to regulate cell cycle through inhibiting CDK1 by phosphorylation on its two different residues Thr14 and Tyr15 [ 5]. Western blot analysis showed that ectopic expression of miR-194 in Hep-2 and KB-3-1 cells obviously downregulated the protein levels of Wee1 as well as the known targets XIAP and p27 [ 3, 6] (Fig.  2a). The predicted interaction between miR-194 and the target sites within the 3’-untranslated regions (3’UTR) of Wee1 was shown in Fig.  2b. We then performed luciferase assay to examine whether there is a direct interaction between miR-194 and Wee1. The wild type or mutant 3’UTR region of Wee1 were cloned into downstream of the firefly luciferase gene to generate the luciferase reporter vectors. As illustrated in Fig.  2c, ectopic expression of miR-194 significantly decreased the luciferase activity of wild type 3’UTR, but not mutant 3’UTR in Hep-2 and KB-3-1 cells, suggesting that the putative miRNA binding sites of Wee1 are responsible for this miRNA-mRNA interaction (Additional file 1: Figure S1b). Furthermore, analysis of proteins extracted from Hep-2 and KB-3-1 subcutaneous tumors in mice exhibited that the protein levels of Wee1 in miR-194-transduced tumors were remarkably lower than those in vector control (Fig.  2d). In addition, ectopic expression of Wee1 partially reverses the suppressive effects of miR-194 on LSCC cells (Additional file 1: Figure S4a–g).
In summary, our data reveal a potential suppressive role of miR-194 in LSCC by targeting Wee1 in vitro and in vivo. The clinical results indicate that miR-194 can be the potential diagnostic and prognostic biomarkers for LSCC. Our study provides new sights into the role of miR-194/Wee1 axis in LSCC and suggests a novel miR-194/Wee1-based clinical application for LSCC patients.

Acknowledgements

We thank other members of Shi lab and Ye lab for their comments and critical reading of the manuscript.

Funding

This work was supported by funds from the Chinese National Natural Science Foundation Nos. 8161101021, 31271444 and No. 81201726 (Z. S.), the Guangdong Natural Science Funds for Distinguished Young Scholar No. 2014A030306001 (Z. S.) and No. 2014A030313057 (J. Y.), the Guangdong Special Support Program for Young Talent No. 2015TQ01R350 (Z. S.), the Science and Technology Program of Guangdong No. 2016A050502027 (Z. S.) and No. 2013B021800088 (J. Y.), and the Foundation for Research Cultivation and Innovation of Jinan University No. 21616119 (Z. S.).

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Author’s contributions

PL, YY, HL, ZS, and JY designed the experiments, performed the experiments, analyzed the data, and wrote the paper. AKY, JMD, GMT, HFW, JGQ, WJZ, QWJ, DWZ, YC, MNW, JRH, and KW performed the experiments. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

This project was approved by the Ethics Committee of Sun Yat-sen University Cancer Center. Ethics, consent, and permissions: Informed consent was obtained from each patient enrolled in the study. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of Sun Yat-Sen University.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl. 

Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

Journal of Hematology & Oncology 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise